2022
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study.
Ramakrishnan D, Sureshanand S, Pittman B, Radhakrishnan R. Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study. The Journal Of Clinical Psychiatry 2022, 83 PMID: 36044600, DOI: 10.4088/jcp.21m14332.Peer-Reviewed Original ResearchConceptsCOVID-19 outcomesSubstance use disordersOpioid use disorderCOVID-19 patientsAlcohol use disorderRetrospective cohort studyVentilatory supportICU admissionUse disordersHospital admissionPsychiatric diagnosisCohort studyIntensive care unit admissionCOVID-19 positive patientsCare unit admissionLength of hospitalizationLarge health care systemMultivariable logistic regressionHigh-risk groupNumber of hospitalizationsBenzodiazepine use disorderCannabis use disorderUrine toxicology reportsElectronic medical recordsCocaine use disorder
2019
20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME
Radhakrishnan R. 20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME. Schizophrenia Bulletin 2019, 45: s121-s121. PMCID: PMC6455407, DOI: 10.1093/schbul/sbz022.079.Peer-Reviewed Original ResearchFirst-episode psychosisCannabis useReceptor availabilityEU-GEIMeasures of information processingHealthy controlsEU-GEI studyCannabis use resultsPsychosis-spectrum disordersCannabis use disorderPhenotype of schizophreniaRelevant to psychosisRegular cannabis useBrain imaging studiesAssociated with schizophreniaAssessment of behaviorMulti-modal imaging studyPersistent psychosisPsychosis expressionCB1 receptorsCannabis exposureMemory encodingUse disorderPsychosisSchizophrenia
2018
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry 2018, 6: 35-45. PMID: 30528676, DOI: 10.1016/s2215-0366(18)30427-9.Peer-Reviewed Original ResearchConceptsPF-04457845Cannabis withdrawal symptomsFatty acid amide hydrolaseCannabis withdrawalPlacebo groupAdverse eventsCannabis useWithdrawal symptomsFatty acid amide hydrolase inhibitorSerious adverse eventsPhase 2a trialWeeks of treatmentTreatment of cannabisCannabis use disorderSelf-reported cannabis useDSM-IV criteriaTreatment-related differencesTHC-COOH concentrationsAnandamide concentrationsTreat populationPrimary endpointPill countHospital admissionNovel FAAH inhibitorsSelf-reported cannabis